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Removal of ahiminoxamine and ferrioxamine by charcoal hemoperfu-
sion and hemodlalysis. We studied the removal of aluminoxamine (MO)
and ferrioxamine (FO) by (i) hemoperfusion/hemodialysis using an
AluKart in combination with either a Cuprophan F-120 or a He-
mophan' FH-l60 membrane, or (ii) hemodialysis with a high-flux F-60
polysulfone membrane. The same six dialysis patients underwent in a
random order dialysis by the three set-ups after i.v. infusion of 30 mg/kg
of desferrioxamine (DFO) during the last half an hour of the preceding
dialysis session. The mean sri plasma MO and FO clearances of the
AluKart" combined with either a F-120 or FH-160 membrane were
194.3 25.8 mI/mm (AIO) and 164.2 41.3 ml (FO) at the start of
dialysis declining to respectively 76.6 27.3 and 68.5 42.6mI/mm at
the end of dialysis. With a high-flux dialysis membrane the intra-dialytic
plasma clearance remained constant at 81.5 6.8 mI/mm for MO and
60.0 2.8 mI/mm for FO. In the presence of an AluKart" combined
with a FH-160 up to 84 27% and 84 19% of the available AlO and
FO could be removed during a four-hour hemoperfusion/hemodialysis
session. During the first hour of dialysis, respectively 59 and 58% of the
total amount of AIO and FO extracted by the AluKart" was removed
compared to only 9 and 16% during the last hour. We conclude that the
combined use of hemoperfusion/hemodialysis is highly effective fol-
lowed closely by a high-flux F-60 membrane in the removal of AIO and
FO and in combination with low (5 to 10mg/kg) DFO doses, may reduce
the risk for side effects that have been associated with these com-
pounds.
Aluminum (Al) accumulation in hemodialysis patients can
result in Al-induced bone disease, microcytic anemia and
exceptionally in encephalopathy [1]. Recently it was found that
this element may also be responsible for an insufficient response
to erythropoietin treatment observed in some dialysis patients
[2]. In 1980, Ackrill et al [3] used desferrioxamine (DFO), an
iron (Fe) and Al chelating agent, in the treatment of patients
with Al-overload/toxicity. Some studies were done dealing with
the effect of DFO administration on the evolution of the
intradialytic plasma Al levels in the presence of different types
of dialyzers either or not combined with a charcoal hemoper-
fusion cartridge. Using a polysulfone dialyzer, Molitoris et al [4]
observed a higher Al removal after DFO compared to a Cu-
prophan" membrane. McCarthy et al [5] studied the in vitro and
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in vivo characteristics of a coated charcoal hemoperfusion
column in the removal of Al in the presence of DFO. The total
plasma Al clearance with the combined hemodialysis/hemoper-
fusion device was higher than that obtained with the dialyzer
alone. Weiss et al [6], after comparing the Al removal in 17
dialysis patients, concluded that hemofiltration or a combina-
tion of hemodialysis and hemoperfusion should be used to
remove Al in dialysis patients with signs of severe Al-accumu-
lation/toxicity.
After DFO administration in renal failure, ferrioxamine (FO)
has a relatively long plasma half-life [7]. On the other hand, FO
can function as a siderophore to Rhizopus which may cause
mucormycosis a frequently fatal disease [8]. Inter-dialytic
plasma albumin-oxamine (MO) levels are stable and may be
increased at even low DFO doses [7]. Exacerbation of alumi-
num encephalopathy after treatment with desferrioxamine has
been reported [9]. The exact mechanism is unknown but is
theorized to be due to either redistribution of aluminum mobi-
lized by DFO into the brain or to the ability of the AIO complex
to cross the blood/brain barrier. The role of AlO and FO in the
development of other side effects is unknown. Thus, effective
removal of these compounds, in addition to the use of an
optimal DFO dose [7] is mandatory in order to develop an
adequate and safe DFO treatment. In view of this, we studied
the removal of both AlO and FO from the extracellular com-
partment by charcoal hemoperfusion and three dialyzer types
(Cuprophan'. HemophanR, and polysulfone). Aluminoxamine
and FO were measured using a recently developed method [101.
Methods
Patients
Six dialysis patients (3 men, 3 women), aged between 38 and
60 years, were in a random order and with a time interval of at
least two weeks assigned to each of the following setups.
Hemoperfusion/hemodialysis. Hemoperfusion with AluKart'1
(National Medical Care (NMC), Dublin, Ireland) was used in
combination with conventional dialysis using either a standard
Cuprophan' membrane, type Focus F-120 (1.20 m2) (NMC) or
a high-efficiency Focus FH-160 (1.62 m2) Hemophan" mem-
brane (NMC). Charcoal columns contained 80 grams of acti-
vated charcoal (Fig. 1).
1400
Vasilakakjs et al: Removal of aluminoxamine and ferrioxamine in dialysis 1401
Fig. 1. Set up of the hemoperfusion/hemodialysis combination.
Hemodialysis. Hemodialysis using a high-flux F-60 polysul-
fone dialyzer (Fresenius, Bad-Homburg, Germany) was used.
This study was approved by the Ethical Committee of the
Sismanoglion General Hospital, Athens, Greece. Patients gave
informed consent to participation. Patients were ambulant and
in a stable clinical condition. Subjects with liver disease and/or
dialysis dementia were excluded. Aluminum hydroxide therapy
was stopped during the test period.
Studies were conducted on a Fresenius A 2008 C hemodial-
ysis machine, using either bicarbonate (35 mmol/liter; 2 pa-
tients) or acetate dialysate (35 mmol/liter; 4 patients). The blood
flow rate was adjusted to 250 ml per minute while the dialysate
flow was set at 450 ml per minute. Mean SD ultrafiltration
rates were 10.2 4.1; 11.8 3.9 and 9.2 3.0 ml (NS) per
minute for the AluKartR/FH160; AluKart'/F-l2O and F-60,
respectively. The classic two-needle system for vascular access
was used. The post-dialysis body weight of the patients ranged
between 46 and 90 kg (mean SD: 65 14.5 kg). Thirty mg/kg
of DFO (Desferal, Ciba-Geigy, Basle, Switzerland) was admin-
istered intravenously during the last half hour of the dialysis
session preceeding the test session. The harmonic mean and
range of the plasma Al, AlO, Fe and FO levels before DFO, at
the start of the test session (that is, 44 hours after DFO) and the
post-DFO plasma Al increment are presented in Table 1. The
plasma Al increment was determined by making the difference
between the plasma Al concentration of each patient before and
44 hours after (that is, 5 mm before the start of the test session)
DFO administration. Out of these individual data, the harmonic
mean (range) was determined.
Analytical procedures
Blood samples were taken as previously described [10]. In
brief, particular attention was paid to avoid contamination and
every item used during sample taking was regarded and
checked as a potential source of extraneous addition of Al and
Fe. Sample taking was done before the start of the dialysis
session during which DFO was administered, and five minutes
before and 5, 30, 60, 120, 180 and 240 minutes after the start of
the test sessions.
When the AluKartR was used samples were taken at the inlet
(A) (Fig. 1) and the outlet (B) ( inlet dialyzer) of the charcoal
column and at the outlet (C) of the dialyzer. With the polysul-
fone F-60 dialyzer, samples were taken at the inlet (B) and
Table 1. Harmonic mean (range) of the plasma Al, AIO, Fe and FO
levels, and plasma Al increment (N = 6)
AluKartR/
FH-160
AluKart/
F-120 F-60
Before DFO
Al p.mol/ liter 1.8 (0.8—3.1) 1.6 (0.8—3.1) 2.2 (1.l_3.6)a
A1O j.unol/liter 0.0 0.0 0.0
Fe xmol/liter 16.9 (8.0—35.7) 15.1 (6.4—24.8) 18.6 (9.8—50)
FO tsmol/liter 0.0 0.0 0.0
44 hours after DFO
(start dialysis)
Al p.mol/liter 6.8 (3.4—13.0) 6.9 (2.9—15.1) 7.2 (4.7—14.6)
AlO j.unollliter 5.4 (3.0—11.9) 6,4 (3.3—12. 1) 4.9 (3.2—7.9)
Fe p.mol/liier 12.9 (5.4—47.0) 19.6 (10.5—39.5) 18.6 (9.8—43.4)
FO p.mollliter 1.1 (0.7—2.6) 1.7 (1.1—5.6) 1.3 (0.8—2.7)
Plasma Al increment' 4.9 (2.7—10.2) 5.1 (2.1—12.6) 4.7 (3.1—11.0)
i.mol/liter
a p < 0.05 vs. AluKartR/Fl20b Plasma Al increment was determined by making the difference
between the plasma aluminum level of each patient before and 44 hours
after DFO (that is, 5 mm before the start of the test session). Out of
these individual values the harmonic mean (range) was calculated.
outlet (C) of the dialyzer. Dialyzer clearances for the different
compounds were calculated according to the following formula:
Clearance (Cl) = CA-CV/CA x QB + UF.
Here, CA and CV are the arterial and venous concentrations of
the respective compounds (tmol/liter) while QB represents
blood flow (ml/min) and UF the ultrafiltration rate (mllmin).
Because of the relatively small degree of ultrafiltration (± 10 ml
per mm) no correction was made for differences between the
blood flow at the in- and outlet of the dialyzer.
Total AlO and FO removal was assessed as follows:
i6
Removal (fLmol) =
i= I
[t, + — t1) x (CAl + + CA) x Cl1 + 1/2 x 1000],
where i represents the number of sampling set points; (i =
corresponding with the sample taken at zero time; that is, the
start of the test dialysis session).
Assuming that AlO and FO are confined to the extracellular
compartment [11] and that in renal failure this volume contrib-
utes to 20% of the total body weight, the total body burden (BB)
of these compounds at the start of dialysis was estimated using
the formula below:
BB = [(BW x 0.2) + UFv] X CA
Here, BW represents the patients' body weight after dialysis
(kg), UFv corresponds with the total volume of ultrafiltration
(kg) and CA is the arterial plasma concentration of the respec-
tive compounds at the start of dialysis.
Plasma Al and Fe were determined by electrothermal atomic
absorption spectrometry using our previously reported methods
[11, 12]. For the determination of AlO and FO we used an
indirect Zeeman atomic absorption method [10]. Briefly, with
the latter method AlO and FO are selectively extracted into
benzyl alcohol. The Al and Fe concentration of these 1:1
Blood flow
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complexes is then determined in the extraction layer. With this
method, the mean SD recovery of extraction was 98.3 3.7%
for AlO and 101 3.7% for FO. Inter-assay coefficients of
variation of the different compounds in plasma were 5% or less,
while the detection limits were 0.22 j.tmol/liter for AlO and 0.06
tmol/liter for FO.
Statistics
Data are expressed as the mean SD (percentages of
extraction, clearances) or as the harmonic mean (range) for the
non-gaussion distributed data (plasma Al, AlO, Fe and EU
levels, plasma Al increment and absolute amounts of Al, AlO
and FO removed during dialysis). Statistical evaluation was
carried out using the Wilcoxon rank sum test for matched pairs.
A P value <0.05 was considered to be significant at a two-tailed
level.
Results
A three- to fourfold increase in the plasma Al levels was
noted 44 hours after administration of a 30 mg/kg DFO dose
(Table 1, Fig. 2A-C). Plasma Fe at this time point had not
changed significantly. Figure 2A-C furthermore shows tbe
evolution of the plasma Al and Fe levels of the six patients over
time for the different set-ups. The harmonic mean (range)
plasma Al concentrations steadily declined from 6.8 (3.4 to
13.0); 6.9 (2.9 to 15.1) and 7.2 (4.7 to 14.6) tmol/liter, down to
2.3 (1.4 to 3.3); 2.9 (1.3 to 6.4) and 3.0 (2.0 to 5.3) ismol/liter in
the presence of either the AluKartR/FHl60; the AluKart'/F-
120 or the polysulfone F-60 dialyzer, respectively. Intra-dialytic
plasma Fe levels did not change significantly despite a substan-
tial loss of EU.
Forty-four hours after DFO administration 80 10% of the
plasma Al appeared as AlO. Regarding Fe, we noted that only
8.1 0.8% of the total plasma Fe was present as FO (Fig. 3).
The evolution of the mean AlO and FO clearances obtained
with the three set-ups are shown in Figure 4A-B. Using a F-fib
polysulfone membrane plasma AlO and FO clearances re-
mained stable at 81.5 6.8 ml/min and 60.0 2.8 ml/min,
respectively. In the presence of an AluKartR clearances of both
AlO and EU at the start of dialysis were considerably greater,
but, decreased rapidly during the first two hours of dialysis.
Initial clearances were 183.3 25.9 mllmin (AlO) and 140.6
62.9 mI/mm (EU) when using the A1uKart' in combination with
a F-160 dialyzer and 194.3 25.8 mI/mm (AlO) and 164.2 41.3
ml/min (FO) when a F-120 membrane was inserted. At the end
of dialysis, these values had decreased to 76.6 27.3 mI/mm,
83.9 55.8 mI/mm, 83.4 38.0 mI/mm, and 68.5 42.6 mllmin,
respectively. Using the AIuKartR in combination with either a
F-l20 Cuprophan' or a FH-160 Hemophan' dialyzer, total
plasma AlO and FO clearances during the whole course of a
dialysis session were always greater than those obtained using
a polysulfone F-60 membrane alone. On the other hand, plasma
AlO and EU clearances obtained with the latter membrane were
significantly greater than these noted for the F-120 Cuprophan'
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[48.3 5.1 mI/mm (AlO), P < 0.01; 41.0 6.6 mLlmin (FO), P
<0.01] or F-160 HemophanR [60.0 8.6 mllmin (AlO), P <
0,01; 44.3 6.4 mllmin (FO), P < 0.01] dialyzers. The mean
SD plasma AlO clearance with the FH-160 was significantly
greater than that using the conventional F-120 CuprophanR
membrane (P < 0.01). An important observation is that in all
cases plasma AlO clearances tended (on the borderline of
significance; P < 0.05) to be greater than those observed for
FO.
Considering a harmonic mean (range) post-DFO plasma AlO
and FO concentration of 5.4 (3.0 to 11.9) and 1.1 (0.7 to 2.6)
xmolfliter, respectively (Table 1), the total amounts of AlO and
FO removed during a dialysis session using the AluKart'/FH-
160 device were 62.2 (30.4 to 144) and 16.3 (6.8 to 35.5) jxmol
which corresponded to 1.68 (0.82 to 3.39) mg of Al and 0.91
(0.38 to 1.99) mg of Fe (Fig. 5). Corresponding data using an
A1uKart'/F-l20 or a polysulfone F-60 dialyzer were 1.52 (0.64
to 3.82) and 1.37 (0.87 to 1.86) mg of Al and 0.97 (0.53 to 3.4) mg
and 0.46 (0.14 to 1.81) of Fe, respectively. The amounts of AlO
and FO removed by the FH-160 and the F-120 dialyzer alone
were significantly lower (P < 0.05) than those noted for the
AluKartR alone or the F-60 polysulfone dialyzer (Fig. 5).
We calculated that respectively 84 27%, 73 34% and 67
20% (NS) of the total AlO body burden was removed during
a four-hour dialysis session in the presence of an A1uKartR/FH
160; AluKart'/F-l20 or the F-60, respectively. Corresponding
data for FO were 84 19%; 69 28% and 63 22% (NS)
(Table 2). The contribution of the FH- 160 and F- 120 dialyzers in
the total extraction of both AlO and FO never exceeded 30%.
The hourly elimination of AlO and FO is presented in Table
3 indicating that over 50% of the total amount of AlO and FO
removed by the AluKart' was already extracted during the first
hour of treatment, declining to maximally 20% during the last
hour of dialysis.
Discussion
Aluminum accumulation/toxicity is a well recognized clinical
problem in patients with end-stage renal disease. In the therapy
of Al-overload/toxicity all potential sources of Al should be
eliminated (appropriate water treatment, the use of parenteral
fluids with negligible Al contamination, discontinuation or
reduction of oral Al-containing phosphate binders) [13]. Al-
though these preventive measures considerably reduce the
incidence [14] and have, according to some authors [15, 161, a
beneficial effect on the reversal of Al-induced encephalopathy,
osteomalacia and anemia, they are ineffective to remove Al
from the body.
We and others [11, 17] have previously shown that in the
absence of DFO Al is not removed during a routine hemodial-
ysis session. Until now, several studies have been conducted to
investigate the removal of Al [4—6, 17—20] and to a lesser extent
Fe [21, 22] during dialysis after DFO. In this study: (i) the
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Fig. 2. Evolution of the plasma Al (D), Fe (U) and AlO (EJ) and FO
(U) levels in the presence of (A) AluKariR + Hemophan' FH-160
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flux polysulfone dialyzer. Each point represents the harmonic mean
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Fig. 3. Distribution of Al and Fe in plasma
after DFO. Percentages are expressed as the
mean SD of the data of the 6 patients
obtained with the three set ups.
efficacy of a high-flux F-60 polysulfone dialyzer was compared
to that of the hemoperfusion/hemodialysis device using the
AluKartR in combination with either a Hemophan' FH-160 or
Cuprophan' F-l20 dialyzer, and (ii) the removal and clearance
of both the AlO and FO complexes was investigated in (iii) a
paired fashion. Determination of the latter species instead of
elemental Al and Fe is important with regard to side effects such
as the development of mucormycosis [8, 23, 24], ocular and
auditory disturbances [25] and exacerbation of aluminum en-
cephalopathy [9], that have been associated to the formation of
these compounds.
In the present study data on AlO and FO are based on a
validated analytical method having great accuracy and preci-
sion [10]. Its low detection limits and high sensitivity were
largely sufficient for the purpose of this study. Compared to
other techniques, the method is not prone to interferences by
pigments and drugs [26], and does not require laborious proce-
dures for purification and pretreatment of samples [27].
Plasma AlO clearances in the present study, obtained using a
high-flux polysulfone F-60 membrane are in agreement with the
data reported by Molitoris et al [4] showing plasma Al clear-
ances to be around 80.5 7.5 mI/mm in the presence of a
Fresenius high-flux Model F-80 dialyzer, and those of Aarseth
and Ganss [201 reporting the plasma Al clearance of a F-60
membrane to be 34% of a 200 to 250 mI/mm blood flow. It is
worthwhile to note that the plasma AlO clearances obtained
using the polysulfone F-60 membrane were significantly higher
than those using the FH-160 HemophanR dialyzer, which in
turn were significantly greater than those noted with a F-120
CuprophanR membrane. Our data on the plasma AlO clearance
determined using the latter dialyzer are close to the figures
reported for plasma Al by Muirhead et al (39.4 4.1 mlImin)
[19], Simon et al (40.5 9.7 ml/min) [28] and Pierides and
Pierce Myli (37.6 10.8) [29]. However, they are significantly
greater than the data reported by Molitoris et al (20.0 2.8
mi/mm) [4], McCarthy et al (25 2.5 mI/mm) [5] and Chang and
Barre (4.0 17.8 mi/mm) [17]. These discrepancies are most
likely due to the fact that in the latter studies ultrafiltration rates
have not been taken into account.
In contrast to some [5, 6] we placed the AluKart' proximally
to the dialyzer. This set up has the advantage that a better
temperature equilibrium, and electrolyte correction is obtained
in the blood leaving the set up. The counter argument that the
latter set up leads to a more rapid saturation of the cartridge is
not valid, since the evolution of the plasma AlO clearances
observed by us is identical to that reported by others [5, 6] who
inserted the AluKart' post-dialyzer. Moreover, with the set up
used in the present study, plasma AlO clearances by the
AluKartR, determined at the start as well as at the end of
dialysis, were considerably higher than the plasma Al clear-
ances reported using the AIuKart' positioned distal to the
dialyzer [5, 61.
We calculated that for a post-DFO plasma Al increment of 4.9
jimoL'liter (131 jig/liter), up to 1.68 mg of Al could be removed
during a dialysis session when the AluKart' was used in
combination with a FH-160 membrane. The net removal for a
comparable plasma Al increment was 1.37 mg when the F-60
polysulfone dialyzer was used. These figures fit well in the
linear regression curve; Y = 13.8X + 42 (r: 0.9640; N = 27), we
previously [11] established by correlating the plasma Al de-
crease during a four hour dialysis session (X) with the total
amount of Al found in the collected dialysate (Y).
Our data indicate that the AluKartR/hemodialyzer device and
to a less extent the use of a high-flux polysulfone dialyzer are
effective for the removal of Al and may considerably shorten
the duration of DFO therapy for Al overload. The high efficacy
of the hemoperfusion/hemodialysis combination in the removal
of MO and FO must, notwithstanding its saturation effect, be
ascribed to the A1uKart'.
The good performance of the F-60 polysulfone dialyzer is
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Fig. 4. Evolution of the plasma AlO (A) and FO (B) clearances during
a four-hour dialysis session in the presence of AluKartR/FH16O
(O—O); AluKartl?IF12O (•----•); F-60 dialyzer (A----t).
striking with regard to the data in the literature showing that
with a conventional CuprophanR membrane [4, 30] only 25 to
30% of the DFO chelated Al is extracted during a conventional
dialysis session.
From a chemical point of view Al and Fe exhibit a number of
similar characteristics. However, we noted a conspicuous dis-
crepancy with regard to their chelation to DFO. Although in
vitro, Fe has a much greater affinity to DFO than Al [31, 32]
only a small fraction (< 10%) of the total plasma Fe was present
as FO at the start of dialysis 44 hours after DFO administration
whereas 80% of the total plasma Al was DFO-bound. This
indicates that the in vitro affinity of a chelator for a certain metal
is not a reliable index for the in vivo chelation efficacy. In fact,
these observations furthermore indicate that in contrast to Al,
hemodialysis either or not in combination with hemoperfusion
is not effective to lower the Fe status of hemosiderotic patients.
Therefore, the reduction of the plasma ferritin levels [221 or the
decrease in the liver Fe content [33] of hemodialysis patients
after DFO must also be due to intrahepatic iron chelation
followed by biliary elimination of FO during the interdialytic
Table 2. Percentages of the AlO and FO body burden extracted
during dialysis (mean SD; N = 6)
Compound
AluKart'
+
FH-160
AluKartC
+
F-120 F-60 FH-l60 F-120
%
AlO 84±27 73±34 67±20 20±9a l7±4
FO 84 19 69 28 63 22 19 l0 22 lo
P < 0.001 vs. AluKartR/FH.160; AIuKart/F-120 and F-60
period [7], in addition to the removal of the element during
dialysis.
When DFO is administered for Al overload formation of FO
occurs. In dialysis patients, exposure to the latter compound
has been associated with the development of severe and often
fatal infections with non-siderophore producing microorgan-
isms. Recently, Van Cutsem and Boelaert [24] demonstrated an
enhanced growth of two particular Rhizopus strains in the
presence of FO concentrations as low as those encountered in
dialysis patients 44 hours after DFO. Aluminoxamine has been
associated with a deterioration of a patient's encephalopathic
status even at low DFO doses [34]. The role of AlO and FO in
the development of side effects other than the above is not yet
clear. Therefore, because of its high efficacy in the removal of
A
200
150
100
50
0
B
200
150
100
50
0
E
a)
C)C
a)
a)
a)
C)0
E
a)C)C
a)
a)
a)
C)0U-
0 60 120 180 240
A
2.0
- 1.5
a)
C)
a)
! 1.0
0
C
0.5
E
0
Time, minutes
1.0
a)
0.5
0
AluKart®/FH-160 AluKart®/F-1 20 Fresenius F-60
0 60 120 180 240 Fig. 5. Amounts of AlO and FO extracted using the three set-ups.
Symbols are: () dialyzer; ()AluKart'; (•) total.
Time, minutes
AluKart®/FH-160 AluKart!sIF-120 Fresenius F-60
I
1406 Vasilakakis et a!: Removal of aluminoxamine and ferrioxamine in dialysis
Table 3. louny elimination (%) of Al0 and FO during dialysis by the three setups
1 2 3 4
Hours: AlO FO AlO FO MO P0 AlO P0
MuKartR + FH-160
AluKant1t
FH-160
51.2
58.6
32.1
44.3
46.5
28.4
24.0
21.4
25.8
22.5
21.1
31.2
14.6
11.4
22.8
16.9
16.4
24,7
10.2
9.4
18.3
16.6
16.0
15.6
AluKartR + F-120
AluKart't
F-120
44.8
52.2
35.5
45.5
57.6
18.6
23.4
20.1
34.9
22.3
16.8
30.6
19.5
18.3
18.3
18.7
16.1
26.6
12.2
9.3
21.3
13.4
9.5
24.2
F-60 39.3 30.5 25.6 25.2 18.8 23.6 16.3 20.5
both the FO- and AlO-complexes, the hemoperfusion/hemodi-
alysis setup and to a lesser extend the use of a high-flux
polysulfone dialyzer will limit the exposure of dialysis patients
to these compounds and in combination with low DFO doses,
will reduce the putative risk for side effects, thus providing a
safer therapy for Al overload.
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